Adjuvant

HER2-

Triple Negative

NRGBR003
Doxorubicin Hydrochloride and Cyclophosphamide + Paclitaxel +/- Carboplatin in 3-Neg Breast Cancer
PI: Wapnir NRG

Prior Neo-Adjuvant TX

ECOG-ACRIN-S1418
Phase III MK-3475(Adjuvant Tx) Triple Receptor-Negative Breast Cancer After Neoadjuvant Chemotherapy
PI: Telli ECOG-ACRIN

ECOGBS55
Phase III Olaparib as Adjuvant Tx in Germline BRCA Mutated High Risk HER2 Neg Primary Breast Cancer
PI: Telli ECOG-ACRIN

BRCA+

ECOG-ACRIN-PRE010
Phase III Standard Adjuvant Endocrine Treatment +/- Palbociclib in HR+ / HER2- Early Breast Cancer
PI: Massanweh PreECOG

ER/PR+

KEY

Pending
Open for Enrollment
Observational Study
Optional Path
Link
Trial Posting
Extension Study
Immunotherapy
Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu